NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical… EP News Bureau Jul 25, 2024 According to GlobalData, NewAmsterdam’s obicetrapib is expected to be the most promising agent to launch in the dyslipidemia…
Long road ahead for non-statin therapies in Australia dyslipidemia treatment space: GlobalData EP News Bureau Mar 15, 2023 According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in…
